A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

Inclusion Criteria: * Age: Healthy males and/or females aged 18 to 55 (inclusive) at consent signing. * Certified healthy based on history, physical exam, vitals, ECG, and labs with no abnormalities. * Weight: 50-100 kg (male), 40-90 kg (female); BMI 18-30 kg/m² inclusive. * Sex-based eligibility: All males must use effective contraception or remain abstinent and avoid sperm donation for 3 months post-dose. Females must use highly effective contraception, not be pregnant or breastfeeding, and test negative for pregnancy before treatment. Exclusion Criteria: * History of significant systemic diseases (hematologic, renal, endocrine, pulmonary, GI, cardiac, hepatic, psychiatric, neurologic, infectious, allergic; except mild seasonal allergies). * Clinically significant ECG abnormalities. * Frequent headaches or migraines, and recurrent nausea or vomiting (over twice monthly). * Blood donation within 2 months. * Symptomatic or significant postural hypotension. * Drug hypersensitivity or significant allergies, including to study drugs. * History of drug/alcohol abuse. * Tobacco use within 3 months prior to Day 1. * History of Hepatitis B/C, TB, or invasive opportunistic infections. * Malignancy within 5 years (except treated non-metastatic skin cancer). * Adverse reaction to balinatunfib, moxifloxacin, or quinolones. * Any medication (except hormonal contraception/HRT) within 14 days or 5× half-life. * Biologics within 4 months prior. * Vaccines: non-live within 4 weeks, live w…